COMPANY INFO
Junevity is a biotechnology company founded in 2023 at UCSF. The founders are John Hoekman, Janine Sengstack, Rob Cahill, and Hao Li. The company has 13 employees and is headquartered in San Francisco, CA. Junevity operates in the Biotechnology industry and develops cell reset therapeutics aimed at extending healthspan and lifespan by reversing diseases of aging through novel transcription factor medicines using large-scale human data and artificial intelligence. (junevity.com, pitchbook.com)
Junevity is a biotechnology company founded in 2023 at UCSF, focused on developing cell reset therapeutics aimed at extending healthspan and lifespan. Junevity leverages novel transcription factor medicines, large-scale human data, and artificial intelligence to reverse diseases of aging.
Junevity executives and the broader leadership team bring together deep scientific expertise, industry experience, and innovative business strategies to advance the company's mission. The Junevity management team, including its founders, draws on their backgrounds in genomics, advanced therapeutics, and biotechnology to drive scientific breakthroughs, foster cross-industry partnerships, and steer the growth of the company within the competitive longevity market.
As Co-founder and Chief Scientific Officer, Janine Sengstack leads the scientific direction at Junevity, spearheading the development of gene-targeting therapeutics designed to reset cellular health for longevity. Janine Sengstack transitioned from CEO to CSO to focus on scientific innovation, leveraging discoveries from her UCSF research to develop siRNA therapeutics targeting transcription factors related to aging—a central pillar of Junevity's technology and growth.
Janine holds a PhD from University of California, San Francisco, where she pioneered research on genes capable of reversing cellular aging markers. With a summa cum laude BS in Biology from California Polytechnic State University-San Luis Obispo, Janine's accolades include winning the Scientific Excellence Award in the Nucleate Activator Program and securing industry experience as a Genentech intern, giving her a robust foundation in genomics and therapeutics.
Rob C. is a Co-founder of Junevity, where he has played a critical role in strategic execution and business development, solidifying the company’s place in the biotechnology industry. Rob has driven partnerships and led crucial projects, helping to secure growth and industry presence by combining strategic vision with operational know-how.
Previously a chief of staff and business development leader at SunRun, Rob's experience includes driving partnerships, managing national press coverage, and leading federal funding initiatives. His strong business development background and leadership skills have contributed significantly to the success and scalability of the Junevity management team.
Dr. Yi Jin leads siRNA therapeutic development at Junevity, guiding the discovery and advancement of RNA-based therapies. Yi Jin's 20+ years of oligonucleotide therapeutics expertise have been crucial in building Junevity's robust platform and therapeutic pipeline, while her leadership ensures continued innovation and the scalability of manufacturing for clinical needs.
Yi Jin earned her Ph.D. in nucleic acid chemistry from McGill University. Before joining Junevity leadership, she served as Scientific Director at Johnson & Johnson Innovative Medicine and as Executive VP at Suzhou Ribo Life Science, making her a leading expert in siRNA drug development and RNA therapeutics commercialization.
Dr. Charu Shukla Reddy is Principal Scientist responsible for leading preclinical research initiatives at Junevity, supporting critical translational biology and hypothesis-driven studies. Charu's contributions enhance the rigor of Junevity's therapeutic development, ensuring robust pathways from research to clinical advance.
Charu holds a Ph.D. in Cell Biology and Neuroscience from Kent State University and completed a postdoctoral fellowship at Harvard Medical School. Her diverse experience covers molecular biology, neuroendocrinology, translational biology, and includes prior roles at Codexis and Sorrento Therapeutics, fortifying Junevity management with deep scientific insight.
Molly Kaeding is a Research Scientist at Junevity, focusing on developing siRNA therapeutics for age-related diseases. She is integral to Junevity's R&D and preclinical development efforts, contributing to the progression and validation of therapeutic candidates tied to the company’s core mission.
Molly has accumulated more than six years of biotechnology and healthcare experience in roles at Nkarta, Stanford Health Care, and NASA Ames Research Center. She holds a BS in Molecular Biology from California Polytechnic State University-San Luis Obispo and an MS in Biochemistry and Molecular Biology from Georgetown University.
L'erin Moore, as Preclinical Associate Scientist, supports the evaluation and scientific experimentation essential for Junevity’s therapeutic candidate advancements. Her skill in detailed research and data analysis ensures the scientific rigor underpinning Junevity’s preclinical pipeline.
L'erin brings experience from roles at Gilead Sciences and Northwestern University and holds advanced certifications in leadership and interpersonal communication. Her technical expertise supports research technology and product development within Junevity management.
Alyssa Amezquita is a key contributor in early-stage research and assay development, helping identify and validate novel therapeutic targets for Junevity. Her work drives discoveries that shape the Junevity pipeline and future strategies for cellular therapeutics.
Alyssa graduated with a BS in Molecular and Medical Microbiology from UC Davis, bringing assay development, flow cytometry, and CRISPR-based genome editing experience gained at GigaMune and Scribe Biosciences to her work at Junevity.
John Hoekman is a senior executive at Junevity, providing strategic guidance and industry connections for collaborative projects and public engagement. He contributes broadly to strategic initiatives and maintains an active presence at biotech industry events.
John benefits from an extensive network and longstanding participation in biotech conferences and showcases, and his influence supports both the reputation and industry collaborations vital to Junevity’s continued expansion.
Carley Hendriks, Scientist at Junevity, drives innovation in CRISPR and nucleic acid technologies, supporting Junevity’s gene editing and therapeutic discovery efforts. Her input contributes directly to the scientific creativity embedded in Junevity’s research and development.
Carley earned a B.S. in Biochemistry from University of Oregon and previously worked at Mammoth Biosciences in CRISPR research. She is also an inventor on several patents related to nucleic acid detection and gene-editing technologies.
The Junevity leadership team features a blend of scientific founders, biotech R&D experts, and strategic business leaders. This diverse management structure ensures comprehensive oversight of both scientific innovation and commercial strategy. With a small but highly specialized team, Junevity executives focus on efficient collaboration, rapid advancement from discovery through preclinical stages, and alignment around the mission to expand healthspan with groundbreaking therapeutics. The company values interdisciplinary expertise and entrepreneurial drive, reflected in the caliber and cohesion of its executive group.
Websets is a powerful natural language search and data enrichment tool that helps you research executive teams for any company. Whether you're analyzing the Junevity leadership team or exploring management structures at other organizations, Websets provides comprehensive insights into executive backgrounds, roles, and team dynamics.
With Websets, you can access detailed executive team profiles, management structures, and leadership insights through intuitive natural language queries. Sign up now to enhance your executive team research capabilities.